Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and ...

NYSE American announced that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Scorpius ...

Scorpius Holdings, Inc. faces delisting from NYSE American due to low stock price and late Form 10-K filing, plans to appeal. Scorpius Holdings, Inc. has announced that the NYSE American is ...

San Antonio, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing ...

Scorpius Holdings, Inc., a pharmaceutical company whose stock has plunged 99.58% over the past year to $0.13, has been notified of non-compliance with NYSE American’s continued listing standards due ...

San Antonio, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing ...

Scorpius Holdings Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond.